SABCS 2022 Conference Coverage
Playback speed
10 seconds
SABCS 2022 Results of the Randomized, Multi-Dose Phase 2 SERENA-2 Trial: Camizestrant, a Next-Gen Oral SERD vs. Fulvestrant in Post-Menopausal Women With Advanced ER+/HER2- BC
By
SABCS 2022 Conference Coverage
FEATURING
Mafalda Oliveira
By
SABCS 2022 Conference Coverage
FEATURING
Mafalda Oliveira
237 views
December 15, 2022
Comments 0
Login to view comments.
Click here to Login
Videos